Abstract
INTRODUCTION
Hepatic fibrosis is a wound-healing pathological process resulting from chronic hepatic injuries, which is characterized by the accumulation of extracellular matrix (ECM) [1] . It occurs during most continuous and chronic liver diseases, driven by inflammatory responses to tissue injury, which ultimately lead to liver cirrhosis. Previous studies indicated that activation of hepatic stellate cells (HSCs) plays an important role in the progress of hepatic fibrosis [2, 3] . Activation of HSCs increases cell proliferation, producing large amounts of ECM components including hexadecenoic acid (HA) and laminin (LN) [4, 5] . In addition, aberrant activity of transforming growth factor β1 (TGF-β1) or members of the platelet derived growth factor family are also the most prominent drivers to activate and transdifferent HSCs into myofibroblast [6, 7] . Further, several chemokines that modulate the inflammatory reaction are involved in the progression of HSC activation and the fibrotic insult [8, 9] . Many studies have demonstrated that the reversion of fibrosis can be achieved, particularly in the early course of the disease. Currently, treatment of liver damage mainly consists of inhibiting early activation and proliferation of HSCs and collagen fiber growth, and promoting HSC apoptosis and collagen degradation.
Many studies indicated that Foeniculum vulgare root bark (FVRB), a traditional Uyghur medicine, contains many chemical constituents, such as saccharides, glycosides, lactone compounds, phenols, tannins, flavonoids, alkaloids, volatile oil, grease, triterpenes and sterols [10, 11] . In addition, FVRB has been traditionally used for the treatment of several pathophysiological conditions in China, exhibiting the activity of dispelling coldness, warming kidney and stomach, removing dampness, and alleviating swelling and pain [12] [13] [14] [15] .
For the first time, the present study was aimed to investigate the protective effects of FVRB against CCl4-induced liver injury in vivo and the possible mechanisms involved.
MATERIALS AND METHODS

Animals
Male Kunming mice weighing 20 ± 2 g were supplied by the Experimental Animal Center of Urumqi (Urumqi, China). Mice were housed at room temperature under a 12 h light/dark cycle (lights on at 08:00 h) and were fed a standard diet ad libitum. All animal care and experimental procedures were approved by the Institute Ethnics Committee of Shihezi University. Rabbit primary antibodies against TGF-β1, alphasmooth muscle actin (α-SMA), matrix metalloprotein 9 (MMP-9), and metallopeptidase inhibitor 1 (TIMP-1), and horseradish peroxidase labeled secondary antibody were purchased from BOSTER (Wuhan, China).
Drug material
Experimental protocol
Mice were randomly divided into eight groups (n = 20 each): A-H. Group A (normal control group) was allowed free access to water and food. In the other seven experimental groups (B-H), the mice were treated with CCl4 (10 mL/kg, i.p.) in olive oil (1:1000, v/v), twice a week for eight weeks. Group B served as a solvent control group, in which mice were given olive oil at 10 mL/kg at the fifth week. Group C was a model group, in which mice were given water at 10 mL/kg at the fifth week. Groups D, E, F, and G were orally administered with FVRB (88, 176, 352 and 704 mg/kg, respectively) once daily from the fifth week for four weeks. Group H was a positive control group, in which mice were treated with Yiganling Pian (200 mg/kg). Mice were anesthetized with ethyl ether and blood samples were harvested. The blood was centrifuged at 3500 rpm for 10 min at 4 ℃ to obtain the supernatant serum, which was stored at 80 ℃ until further use for biochemical analysis. Liver, spleen and kidney were dissected out and washed immediately with ice cold saline to weigh.
Biochemical analysis
Serum was collected as mentioned above. ALT, AST and TG were determined according to the manufacturer's protocols using a Microplate Reader Thermo 3001. The absorbance of ALT and AST reactions was read at 505 nm and the absorbance of TG reaction was read at 546 nm. The enzyme activity is calculated as U/L. HA and LN levels were determined by enzyme-linked immunosorbent assay using the commercial kits. The absorbance of the reaction was read at 450 nm.
Measurement of MDA, GSH and SOD activities
Liver tissues samples were homogenized in physiological saline to give a 10% (w/v) liver homogenate, which was then centrifuged at 2500 rpm for 15 min at 4 ℃. The supernatant was used for the measurement of MDA, GSH and SOD activities with the commercial kits following the manufacture's protocols. Data are expressed as U/mg of protein.
Histopathological evaluation
Liver specimens were fixed in 10% formalin and then embedded in paraffin. Four-micrometer-thick sections were obtained from paraffin blocks and stained with hematoxylin and eosin (H and E) and Masson's trichrome (MT) before they were examined under a light microscope. The images were randomly taken from ten fields under a light microscope (200 × magnification).
Immunohistochemistry
TGF-β1, MMP-9 and TIMP-1 expression levels in the liver were measured by immunohistochemistry. The liver tissues were sectioned and incubated with rabbit anti-TGF-β1 antibody (1:100), rabbit anti-MMP-9 antibody (1:100), and rabbit anti-TIMP-1 antibody (1:100). Then the slides were processed using an immunohistochemical staining kit. After that, the slides were counterstained with hematoxylin and mounted with a glycerin gel. In the negative control groups, the primary antibodies were replaced with PBS. The sections were observed under a microscope (Nikon 80i).
Western blot analysis
Total protein was extracted from the liver tissue and the protein concentration was determination by BCA method. The protein was separated by SDSpolyacrylamide gel electrophoresis, followed by transfer to PVDF membrane. The membranes were blocked with 5% nonfat milk in TBST buffer for 1 h. Then target proteins were incubated overnight at 4 ℃ with TGF-β1 and α-SMA primary antibodies (1:1000). After washing four times with TBST, the membranes were incubated with HRP-conjugated secondary antibody (1:10000) for 1 h at room temperature. Then the membranes were immersed in an enhanced chemiluminescence detection solution. Protein was analyzed by the gray value of the band, which is expressed as the ratio of the target protein and the β-actin protein.
Statistical analysis
All quantitative data are expressed as mean ± SE. Data were analyzed with SPSS 13.0 software. Statistical significance between groups was determined by oneway analysis of variance (ANOVA) followed by Tukey's multiple range post hoc test. P < 0.05 was considered statistically significant.
RESULTS
Effect of FVRB on organ index increase induced by CCl4 treatment
As demonstrated in Figure 1 , organ indexes including liver, spleen and kidney coefficients were measured in mice. Similar to previous studies [16] , liver and spleen indexes were significantly increased in mice treated with CCl4. Compared with the model group, the increase of liver index and spleen index in CCl4-treated group was reduced by FVRB and Yiganling Pian treatment. However, there were no significant
Effect of FVRB on serum HA and LN in mice
After CCl4 administration, the levels of serum HA and LN were significantly increased as compared with the normal control group (P < 0.05; Figure 4 ). Treatment with Yiganling Pian (200 mg/kg) significantly decreased the levels of serum HA and LN (P < 0.05; Figure 4 ). Meanwhile, FVRB treatment markedly decreased the elevation of serum HA and LN in a dose-dependent manner after long-term CCl4 injection in mice (P < 0.05; Figure 4 ).
Effect of FVRB on histopathological alterations
As shown in Figure 5A , the liver sections of the normal control group exhibited the normal cellular structure with well-preserved cytoplasm, prominent nucleolus and central vein. In contrast, the liver sections of the CCl4-treated group and solvent control group exhibited significant pathological changes, such as fibrosis, ballooning degeneration, steatosis, disseminated macrovesicular and microvesicular changes ( Figure 5B and C). There was focal necrosis as well as piecemeal necrosis and fibrosis of portal areas. However, the FVRB and Yiganling Pian treatment groups showed a few to milder degree of leukocytes infiltration and necrosis ( Figure 5E -H). In addition, as compared to the normal control group, the livers of mice treated with CCl4 and the solvent exhibited extensive accumulation of connective tissue, leading to the formation of continuous fibrotic septa, nodules of regeneration, and noticeable alterations in the central vein ( Figure 6A-C) . However, treatment with FVRB and Yiganling Pian significantly attenuated CCl4-induced alterations ( Figure 6E -H). The severe hepatic fibrosis was reduced by treatment with FVRB, which was in good correlation with the results of hepatic antioxidant enzyme activities and serum aminotransferase activities.
differences in the kidney coefficient between the groups.
Effect of FVRB on serum AST, ALT and TG activities in mice
As shown in Figure 2 , CCl4 treatment markedly elevated serum AST, ALT and TG activities as compared with the normal control group. The AST and ALT activities after CCl4 treatment were about 5 and 4 times higher than that of the normal group, respectively. However, Yiganling Pian treatment markedly inhibited the increase of serum AST, ALT and TG after long-term CCl4 injection in mice (P < 0.05; Figure 2) . Similarly, the administration of FVRB at different dosages significantly decreased AST, and ALT and TG activities (P < 0.05 or P < 0.01; Figure 2 ).
Effect of FVRB on MDA, GSH and SOD levels in CCl4-treated mice
Lipid peroxidation was evaluated by measuring MDA content in liver tissue. In the CCl4 treatment group, the content of MDA was elevated as compared with the normal control group. The administration of FVRB significantly decreased MDA content in a dosedependent manner. Also, as compared with the normal control group, CCl4 treatment markedly decreased the GSH level and SOD activity in liver tissue. However, treatment with the extract of FVRB (352 and 704 mg/kg) markedly recovered the CCl4-induced GSH depletion (P < 0.01; Figure 3 ). In addition, FVRB treatment (88, 176, 352 and 704 mg/kg) significantly restored the depletion of SOD activity in a dosedependent manner (Figure 3) . Similarly, Yiganling Pian treatment (200 mg/kg) increased the GSH content and SOD activity as compared with the CCl4 group (P < 0.01; Figure 3 ). Further, there was no significant difference in the levels of MDA, GSH and SOD between the CCl4 group and the solvent control group. 
Effect of FVRB on immunohistochemical staining for TGF-β1, MMP-9 and TIMP-1
As shown in Figure 7A , the expression of TGF-β1 in the normal control group was only observed in the portal area and central vein, with a relatively shallow, narrow range. In Figure 7B and C, the expression of TGF-β1 in the model group was mainly distributed in the portal area and central vein, with brown granules showing a wide distribution. However, the positive expression of TGF-β1 was significantly decreased in the FVRB treatment group (Figure 7D-G) . The positive control group also showed a good reduction in the expression of TGF-β1 ( Figure 7H ).
Immunohistochemical expression of MMP-9 protein is shown in Figure 8 . Positive MMP-9 staining appeased as brown granules in the cytoplasm and membrane. The overall color of the normal group was light brown, while the model group was significantly different. Compared with the model group, the positive expression in the treatment group was decreased, especially in the dose group of 704 mg/kg.
The results of TIMP-1 protein expression are shown in Figure 9 . In the normal control group, there was positive expression of TIMP-1 in peripheral blood vessels and bile duct wall of the portal area ( Figure  9A ). In the solvent group and the model group, the positive staining of TIMP-1 was distributed in the fiber spacing and the central vein, and the brown yellow was obviously visible (Figure 9B 
Effect of FVRB on TGF-β1 and α-SMA protein expression
As illustrated in Figure 10 , compared to the normal control group, the expression of TGF-β1 and α-SMA in the CCl4 treatment group was significantly increased (P < 0.01). However, FVRB treatment markedly decreased TGF-β1 and α-SMA expression as compared with the CCl4 treatment group (P < 0.05 or P < 0.01). Meanwhile, treatment with Yiganling Pian also significantly attenuated TGF-β1 and α-SMA expression (P < 0.01).
DISCUSSION
Liver fibrosis is usually regarded as an outcome of chronic liver injury in the process of long-term wound healing [17] [18] [19] . In the present study, CCl4-induced liver injury, the most commonly used model for hepatic fibrosis [20, 21] , was induced. We detected the levels of ALT, AST, TG, HA and LN to assess liver function and the degree of liver fibrosis. There is evidence that natural substances may have a protective role against CCl4-induced liver injury [22, 23] . Considerable efforts have been made in the study of natural products with hepatoprotective activities [24, 25] . Our study showed that CCl4 caused a significant increase in serum levels of ALT, AST, TG, HA and LN in mice. However, FVRB treatment significantly altered these trends. Its hepatoprotective effect was further confirmed by histopathological observation that FVRB attenuated CCl4-induced necroinflammatory and fibrogenic effects.
There is growing evidence that oxidative stress contributes to the development of liver fibrosis by activating various signaling pathways involved in fibrogenesis [26, 27] . The tissue concentration of MDA, a product of lipid peroxidation during liver fibrogenesis, was assayed. Also, the SOD and GSH activities were measured. In the present study, in the CCl4-treated mice, the MDA level in liver tissue was elevated and the activities of SOD and GSH were decreased. Reversal of these trends by FVRB treatment suggests that FVRB prevented the progression of liver fibrosis by inhibiting oxidative stress in the liver.
The histopathological studies are a direct means for assessing the protective effect of FVRB. HE and Masson staining results showed that FVRB could reduce liver necrosis, significantly inhibit collagen fiber hyperplasia, improve liver tissue structure and reduce fiber tissue. These results further confirmed that FVRB dose-dependently decreased hepatic histopathological changes.
The activation of HSCs is the central event in the pathogenesis of liver fibrosis [28] [29] [30] . In recent years, many studies found that TGF-β1 is the strongest factor inducing fibrosis, and it is also an important factor to promote the activation of HSCs [28, 31] . Our result confirmed that administration of FVRB reduced the expression of TGF-β1 protein. Therefore, the anti-fibrotic effect of FVRB may be mediated by its inhibitory effect on TGF-β1. In addition, α-SMA expression also increases the generation and proliferation of chemotactic factors that are capable of recruiting inflammatory cells [32, 33] . From the results we know that expression of α-SMA was enhanced by CCl4 treatment, while the administration of FVRB prevented the development of fibrosis perhaps through the inhibition of α-SMA.
The major pathological change of liver fibrosis is the excessive accumulation of collagen and other extracellular matrixes [34] . Under normal circumstances, the synthesis and decomposition of collagen is balanced. Once the synthesis is over than decomposition, it will cause the accumulation of collagen in the liver, leading to the formation of liver fibrosis [35] . Matrix metalloproteinases (MMPs) can promote the degradation of extracellular matrix, which is consistent with the previous finding that the tissue inhibitors of metalloproteinase (TIMPs) can reduce liver fibrosis severity [36, 37] . Among the MMP family members, MMP-9 plays an essential role in fibrosis formation. Many studies have shown that MMP-9 is elevated in patients with liver fibrosis. TIMP-1 can inhibit MMP-9 [38] , preventing the degradation of ECM and thereby promoting liver fibrosis. In the present study, the expression of MMP-9 and TIMP-1 proteins showed significant differences between CCl4 and FVRB treatment groups, which suggests that MMP-9 and TIMP-1 are related to the protective effects of FVRB against the formation of liver fibrosis.
In conclusion, FVRB dose-dependently ameliorated hepatic oxidative stress and suppressed inflammation in CCl4-injured liver fibrosis, and its mechanisms against liver fibrosis may be related with inhibiting lipid peroxidation formation in liver tissue of liver fibrosis mice and reducing the collagen formation by suppressing protein expression of TGF-β1, α-SMA, MMP-9 and TIMP-1. Thus, FVRB may have potential therapeutic utilities for protecting against liver fibrosis. Further experimental studies are necessary to determine the effective constituents of FVRB.
COMMENTS
Background
Hepatic fibrosis is a wound-healing pathological process resulting from chronic hepatic injuries, which is characterized by the accumulation of extracellular matrix. It occurs during most continuous and chronic liver diseases, driven by inflammatory responses to injury tissues, which ultimately lead to liver cirrhosis.
Research frontiers
Currently, treatment of liver damage mainly consists of inhibiting early activation and proliferation of hepatic stellate cells (HSCs) and collagen fiber growth, and promoting HSC apoptosis and collagen degradation. Foeniculum vulgare root bark (FVRB), a traditional Uyghur medicine, has been used for the treatment of several pathophysiological conditions in China, exhibiting the activity of dispelling coldness, warming kidney and stomach, removing dampness, and alleviating swelling and pain.
Innovations and breakthroughs
For the first time, the present study was aimed to investigate the protective effects of FVRB against CCl4-induced liver injury in vivo. And its mechanisms against liver fibrosis may be related with inhibiting lipid peroxidation in liver tissue of liver fibrosis mice and inhibiting the collagen formation by suppressing protein expression of transforming growth factor-β1, alpha-smooth muscle actin, matrix metalloprotein 9 and metallopeptidase inhibitor 1.
Applications
FVRB dose-dependently ameliorated hepatic oxidative stress and suppressed inflammation in CCl4-injured liver injury. Thus, FVRB may have potential therapeutic utilities for protecting against liver fibrosis.
Terminology
Liver fibrosis is usually regarded as an outcome of chronic liver injury in the process of long-term wound healing.
